Atogepant open label data support long term efficacy and safety Sustained response to eptinezumab over 18 months Fresh insights on CGRP mAb and gepant prescribing New data support central action for fremanezumab and ubrogepant Zavegepant reduces need for analgesics AHS recommends anti-CGRP therapies as first line for migraine prevention Imaging data support central effects of erenumab Additive effects of multiple anti-CGRP therapies seen on CGRP-induced vasorelaxation

Fremanezumab

Fremanezumab

In September 2018, Ajovy (fremanezumab) became the second CGRP monoclonal antibody to be approved for the prevention of migraine in adults, and the first and only anti-CGRP therapy with monthly and quarterly dosing options. Approval was supported by data including results of two large Phase 3 clinical trials, one in episodic migraine and the other in chronic migraine. The subsequent Phase 3b FOCUS trial investigated fremanezumab in patients with an inadequate response to 2-4 previous preventive therapies.

Download slideset »

« back to Slides

Educational Partners and Supporters

Lilly

This program is funded in part via an independent educational grant from AbbVie

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2024 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach |